A randomized multinational double-blind placebo-controlled parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis.

Trial Profile

A randomized multinational double-blind placebo-controlled parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Teriflunomide (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2010 Results published at 62nd Annual Meeting of the American Academy of Neurology.
    • 29 Dec 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top